Different administration schedules of darbepoetin alfa affect oxidized and reduced glutathione levels to a similar extent in 5/6 nephrectomized rats
- PMID: 23224027
- DOI: 10.1007/s10157-012-0749-5
Different administration schedules of darbepoetin alfa affect oxidized and reduced glutathione levels to a similar extent in 5/6 nephrectomized rats
Abstract
Background: The development of erythropoiesis-stimulating agents (ESAs) with extended serum half-lives has allowed marked prolongation of the administration intervals. The level of oxidative stress is increased in chronic kidney disease, and is reportedly decreased after long-term ESA treatment. However, the effect of different dosing regimens of ESAs on oxidative stress has not been elucidated.
Methods: Five-sixths nephrectomized (NX) rats received either 0.4 μg/kg darbepoetin alfa (DA) weekly or 0.8 μg/kg DA fortnightly between weeks 4 and 10. NX animals receiving saline and a sham-operated (SHAM) group served as controls. The levels of oxidized and reduced glutathione (GSSG, GSH) were followed from blood samples drawn fortnightly.
Results: During the follow-up, the ratios GSSG/GSH showed similar trends in both DA groups, levels being significantly lower than those in the SHAM group at weeks 8 and 10. GSSG levels were lower than the baseline throughout the study in all groups except for NX controls. The GSH levels were increased in all three NX groups (weeks 6-10) compared with both the baseline and the SHAM group
Conclusion: Our results suggest that the extent of oxidative stress is similar in response to different dosing regimens of DA in 5/6 NX rats when comparable hemoglobin levels are maintained. These findings remain to be confirmed in chronic kidney disease patients.
Similar articles
-
Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial.BMC Cancer. 2010 Oct 25;10:581. doi: 10.1186/1471-2407-10-581. BMC Cancer. 2010. PMID: 20973982 Free PMC article. Clinical Trial.
-
Erythropoiesis-stimulating agent withdrawal and oxidative stress in hemodialysis.Clin Nephrol. 2009 May;71(5):521-6. doi: 10.5414/cnp71521. Clin Nephrol. 2009. PMID: 19473612
-
Subcutaneous administration of darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals in peritoneal dialysis patients.Perit Dial Int. 2009 Mar-Apr;29(2):199-203. Perit Dial Int. 2009. PMID: 19293358 Clinical Trial.
-
An overview of the pharmacokinetic disposition of darbepoetin alfa.Pharmacotherapy. 2002 Sep;22(9 Pt 2):133S-140S. doi: 10.1592/phco.22.14.133s.33396. Pharmacotherapy. 2002. PMID: 12222583 Review.
-
Drug safety profile of darbepoetin alfa for anemia of chronic kidney disease.Expert Opin Drug Saf. 2009 Mar;8(2):145-53. doi: 10.1517/14740330902793031. Expert Opin Drug Saf. 2009. PMID: 19309243 Review.
Cited by
-
Effect of Shenkang granules on the progression of chronic renal failure in 5/6 nephrectomized rats.Exp Ther Med. 2015 Jun;9(6):2034-2042. doi: 10.3892/etm.2015.2383. Epub 2015 Mar 24. Exp Ther Med. 2015. PMID: 26136932 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources